Literature DB >> 10993693

Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.

J L Eberling1, P Pivirotto, J Bringas, K S Bankiewicz.   

Abstract

Unilateral intracarotid artery (ICA) MPTP infusion, along with sequential systemic doses of MPTP, produces near complete degeneration of the nigrostriatal pathway on the side of infusion (ipsilateral) and variable levels of damage in the contralateral hemisphere accompanied by varying levels of parkinsonism (overlesioned hemiparkinsonian model). Positron emission tomography and the dopamine (DA) metabolism tracer [(18)F]6-fluoro-l-m-tyrosine (FMT) were used to evaluate the relationship between DA metabolism and clinical features of parkinsonism in 14 overlesioned hemiparkinsonian monkeys. Monkeys were rated on a parkinsonian scale that included ratings of bradykinesia, fine motor skills (FMS), and rest tremor. Because the monkeys tended to show more severe clinical signs on the side of the body contralateral to ICA MPTP infusion, we calculated asymmetry scores for each of the clinical features as well as for FMT uptake (K(i)) in the caudate and putamen. Tremor asymmetry was associated with FMT uptake asymmetry in the putamen. No such relationship was observed for FMS or bradykinesia. The overall severity of tremor (mild, moderate/severe) was associated with FMT uptake in the caudate and putamen. Postmortem biochemical analysis for a subset of monkeys showed that the monkeys with moderate/severe tremor had significantly lower DA levels in both caudate and putamen than those with mild tremor. In addition, K(i) values were significantly correlated with DA levels in both caudate and putamen. These findings support the idea that nigrostriatal degeneration contributes to rest tremor. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993693     DOI: 10.1006/exnr.2000.7470

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.

Authors:  Catherine L Gallagher; Bradley T Christian; James E Holden; Onofre T Dejesus; Robert J Nickles; Laura Buyan-Dent; Barbara B Bendlin; Sandra J Harding; Charles K Stone; Barb Mueller; Sterling C Johnson
Journal:  Mov Disord       Date:  2011-06-02       Impact factor: 10.338

2.  Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.

Authors:  Navin Maswood; Jennifer Young; Edward Tilmont; Zhiming Zhang; Don M Gash; Greg A Gerhardt; Richard Grondin; George S Roth; Julie Mattison; Mark A Lane; Richard E Carson; Robert M Cohen; Peter R Mouton; Christopher Quigley; Mark P Mattson; Donald K Ingram
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-16       Impact factor: 11.205

3.  Testing the contributions of striatal dopamine loss to the genesis of parkinsonian signs.

Authors:  Vanessa Franco; Robert S Turner
Journal:  Neurobiol Dis       Date:  2012-03-29       Impact factor: 5.996

4.  Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.

Authors:  Jamie L Eberling; Adrian P Kells; Philip Pivirotto; Janine Beyer; John Bringas; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

Review 5.  Animal models of neurodegenerative disease: insights from in vivo imaging studies.

Authors:  Elissa M Strome; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

6.  PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates.

Authors:  Jamie L Eberling; Krystof S Bankiewicz; James P O'Neil; William J Jagust
Journal:  Front Hum Neurosci       Date:  2008-03-28       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.